Mavorixafor ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群12

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001153-10-GB
(EUCTR)
21/12/202029/06/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
2EUCTR2019-001153-10-DE
(EUCTR)
20/10/202026/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
28Phase 3Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of;United States;Spain;Turkey;Austria;Israel
3EUCTR2019-001153-10-AT
(EUCTR)
16/10/202024/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
4EUCTR2019-001153-10-NL
(EUCTR)
09/09/202006/04/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of
5EUCTR2019-001153-10-PL
(EUCTR)
27/04/202009/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
6EUCTR2019-001153-10-ES
(EUCTR)
02/03/202002/12/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
28 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;United States;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Netherlands;Germany;Korea, Republic of
7EUCTR2019-001153-10-IT
(EUCTR)
18/02/202017/06/2021A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10020986;Term: Hypogammaglobulinemia, unspecified;System Organ Class: 100000004870;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: Mavorixafor
Product Code: [X4P-001]
INN or Proposed INN: Mavorixafor
X4 PHARMACEUTICALS, INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of
8EUCTR2019-001153-10-FR
(EUCTR)
05/02/202016/10/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10010512;Term: Congenital immunodeficiency;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Union;Canada;Belgium;Poland;Romania;Australia;Denmark;Germany;Netherlands;Korea, Republic of
9EUCTR2019-001153-10-HU
(EUCTR)
08/01/202008/11/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
28Phase 3United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Germany;Netherlands;Korea, Republic of
10EUCTR2019-001153-10-DK
(EUCTR)
16/12/201921/10/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor
X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28Phase 3United States;Spain;Austria;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Poland;Denmark;Australia;Germany;Netherlands;Korea, Republic of
11NCT03995108
(ClinicalTrials.gov)
October 17, 201919/6/2019Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label ExtensionWHIM SyndromeDrug: Mavorixafor;Drug: PlaceboX4 PharmaceuticalsNULLActive, not recruiting12 YearsN/AAll28Phase 3United States;Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey
12NCT03005327
(ClinicalTrials.gov)
December 201620/12/2016A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeA Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM SyndromeWHIM SyndromeDrug: X4P-001X4 PharmaceuticalsNULLActive, not recruiting18 YearsN/AAll15Phase 2United States;Australia